|drug96||ARBs and/or ACE inhibitors Wiki||1.00|
|drug3557||Usual Care Wiki||0.32|
There is one clinical trial.
This double blind, placebo controlled, multi-arm, multi-site study investigates the safety and efficacy of stem cell therapy for the treatment of patients admitted to hospital suffering complications from COVID-19 and the treatment of healthy subjects (healthcare providers) for prophylactic effect following those patients.
Description: Survival Rate in COVID-19 infected patients admitted to hospital for complicationsMeasure: Survival Rates Time: 30 Days
Description: Contraction Rate of COVID-19 in healthy healthcare workers following patients admitted to hospital for complications due to COVID-19Measure: Contraction Rates Time: 30 Days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports